# Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia

> **NCT00001197** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 41 (actual)

## Conditions studied

- Sickle Cell Anemia

## Interventions

- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT00001197
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1984-02-07
- **Primary completion:** 2003-12-21
- **Final completion:** 2015-05-18
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001197, "Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00001197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*